乙型肝炎肝硬化并发自发性细菌性腹膜炎患者CD64指数及血清sTREM-1和IL-6水平变化与肠黏膜屏障功能关系研究

doi:10.3969/j.issn.1672-5069.2022.01.020

Abstract

Abstract: Objective The aim of this study was to explore the correlation of blood cluster differentiation (CD) antigen 64 (CD64) index, serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and interleukin-6 (IL-6) levels to intestinal mucosal barrier functions in patients with hepatitis B liver cirrhosis (LC) and spontaneous bacterial peritonitis (SBP). Methods Eighty-six cirrhotics were admitted to our hospital between October 2015 and February 2020, and fifty-four had SBP. The peripheral blood CD64 positive polymorphonuclear neutrophils, lymphocytes and monocytes were detected by flow cytometry and CD64 index was calculated automatically. Serum sTREM-1 and IL-6 levels were detected by ELISA. Blood endotoxin (ETX) and urine lactulose/mannitol (L/M) ratio were detected and calculated to determine intestinal mucosal barrier functions. Results At presentation, serum IL-6, sTREM-1, D-Lac, DAO, EXT as well as blood CD64 index and urine L/M ratio in patients with SBP were(122.1±37.9)ng/L,(60.3±12.4)μg/mL, (5.1±1.6)μg/mL, (14.2±2.2)μg/mL, (0.2±0.0)U/mL as well as (12314.3±324.3)mol/cell and (0.2±0.1), all significantly higher than [(78.6±28.2)ng/L,(51.4±10.6)μg/mL,(2.5±0.8)μg/mL,(9.8±1.6)μg/mL,(0.1±0.0)U/mL as well as (6376.52.5±0.3)mol/cell and (0.1±0.0), respectively, all P<0.05] in LC patients without SBP; after treatment, serum IL-6, sTREM-1, D-Lac, DAO, EXT as well as CD64 index and urine L/M ratio in patients with SBP were (71.2±23.9)ng/L, (17.5±5.1)μg/mL, (2.9±0.8)μg/mL, (14.2±2.2)μg/mL, (0.1±0.0)U/mL as well as (3398.2±258.2)mol/cell and (0.1±0.0), also all significantly higher than[(52.1±21.6)ng/L,(10.8±2.5)μg/mL,(2.3±0.5)μg/mL,(8.7±1.2)μg/mL,(0.0±0.0)U/mL as well as (2541.0±266.2)mol/cell and (0.0±0.0), respectively, all P<0.05] in cirrhotics without SBP; after treatment, serum IL-6 and sTREM-1 levels as well as blood CD64 index in 33 SBP patients with disabled intestinal mucosal barrier functions were(75.2±24.1)pg/mL and (19.5±4.9)μg/mL as well as (3642.2±242.1)mol/cell, all significantly higher than [(65.2±21.3)pg/mL and (14.8±4.3)μg/mL as well as (3123.2±168.4)mol/cell, respectively, P<0.05] in 21 patients with normal intestinal mucosal barrier functions. Conclusion The LC patients with SBP have abnormal intestinal mucosal barrier functions, which might take part in the pathogenesis of bacterial translocation.

Key words: Liver cirrhosis, Spontaneous bacterial peritonitis, CD64 index, Soluble triggering receptor expressed on myeloid cells-1, Interleukin-6, Intestinal mucosal barrier functions

Wang Jing, Bi Ning, Fang Liang, et al. Correlation of blood CD64 index to intestinal mucosal barrier functions in patients with hepatitis B cirrhosis and spontaneous bacterial peritonitis[J]. Journal of Practical Hepatology, 2022, 25(1): 79-82.

References

[1] 金军,宋震宇,刘吉祥.乙型肝炎肝硬化患者血清IL-10和可溶性细胞间黏附分子-1水平和其对疾病预后的判断价值.实用肝脏病杂志,2019,22(4):549-552.
[2] Wong YJ, Kalki RC, Lin KW, et al. Short- and long-term predictors of spontaneous bacterial peritonitis in Singapore. SingaporeMed J,2020,61(8):419-425.
[3] Elloumi H, Sabbah M, Bibani N, et al. Effect of low dose albumin administration in spontaneous bacterial peritonitis on renal function and survival. Arab J Gastroenterol,2019,20(4):205-208.
[4] Chen PC, Chen BH, Huang CH, et al. Integrated model for end-stage liver disease maybe superior to some other model for end-stage liver disease-based systems in addition to Child-Turcotte-Pugh and albumin-bilirubin scores in patients with hepatitis b virus-related liver cirrhosis and spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol,2019,31(10):1256-1263.
[5] 彭官清,凌乔,潘沛沛, 等.肝硬化并发自发性细菌性腹膜炎患者血清中颗粒蛋白前体水平和临床意义.中华医院感染学杂志,2019,29(23):3558-3562.
[6] Devani K, Charilaou P, Jaiswal P, et al. Trends in hospitalization, acute kidney injury, and mortality in patients with spontaneous bacterial peritonitis. J Clin Gastroenterol,2019,53(2):68-74.
[7] Zhao S, Xu W, Xie YX, et al. CXCR5⁺ CD4⁺ T cell subsets and their relationship to immune dysfunction in chronic hepatitis B-associated liver cirrhosis. J Gastroenterol Hepatol,2020,35(4):689-695.
[8] García-Salido A, Serrano-González A, de Azagra-Garde AM, et al. Flow cytometry analysis of CD64, CD18, CD11a and CD11b in four children with Bordetella Pertussis infection and admitted to critical care: new biomarkers? Med Intensiv,2019,43(7):446-449.
[9] Cao QY, Guo XY, Duan JA, et al. The active fraction from the tuber ofBolboschoenus Yagara inhibits melanoma B16 cells metastasis LPS-induced in vitro and in vivo. Nat Prod Res,2020,34(23):3378-3381.
[10] 中华医学会肝病学分会. 肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-792.
[11] 张继明,翁心华.自发性细菌性腹膜炎的诊断和防治.中华肝脏病杂志,2005,13(6):459-460.
[12] 中华医学会消化病学分会.肠屏障功能障碍临床诊治建议.中华消化杂志,2006,26(9):620.
[13] Weil D, Heurgue-Berlot A, Monnet E, et al. Accuracy of calprotectin using the Quantum Blue Reader for the diagnosis of spontaneous bacterial peritonitis in liver cirrhosis. Hepatol Res,2019,49(1):72-81.
[14] Tulkens J, Vergauwen G, Van Deun J, et al. Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction.Gut,2020,69(1):191-193.
[15] Raschi E, Privitera D, Bodio C, et al. Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. Arthritis Res Ther,2020,22(1):265.
[16] Menshawy A, Mattar O, Barssoum K, et al. Safety and efficacy of rifaximin in prophylaxis of spontaneous bacterial peritonitis: a systematic review and meta-analysis. Curr Drug Targets,2019,20(4):380-387.
[17] Jana S, Chattopadhyay S, Dey A, et al. Involvement of metallothionein, homocysteine and B-vitamins in the attenuation of arsenic-induced uterine disorders in response to the oral application of hydro-ethanolic extract of Moringa oleifera seed: a preliminary study. Drug Chem Toxicol,2020,43(1):1-12.
[18] Edogawa S, Edwinson AL, Peters SA, et al. Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS. Gut,2020,69(1):62-73.
[19] Saia RS, Ribeiro AB, Giusti H. Cholecystokinin modulates the mucosal inflammatory response and preventsthe lipopolysaccharide-induced intestinal epithelial barrier dysfunction. Shock,2020,53(2):242-251.
[20] Forrester DL, Barr HL, Fogarty A, et al. sTREM-1 is elevated in cystic fibrosis and correlates with proteases. Pediatr Pulmonol,2017,52(4):467-471.
[21] 张正宝,沈晓菲,曹科, 等.腹水可溶性髓系细胞触发受体-1在诊断肝硬化后细菌性腹膜炎的价值.中华消化杂志,2017,37(5):336-337.

Correlation of blood CD64 index to intestinal mucosal barrier functions in patients with hepatitis B cirrhosis and spontaneous bacterial peritonitis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zeng Yi, Li Guo, Li Hongcui, et al. Efficacy of ursodeoxycholic acid in the treatment of patients with primary biliary cholangitis and cirrhosis and its effect on serum Nrf2 and HO-1 levels [J]. Journal of Practical Hepatology, 2022, 25(2): 211-214.
[2]	Hao Yuting, Lin Jie, Qin Jie. Clinical implication of serum aquaporin-8 and aquaporin-9 in patients with hepatitis B-induced liver cirrhosis receiving long-term entecavir therapy [J]. Journal of Practical Hepatology, 2022, 25(2): 243-246.
[3]	Wang Benxian, Li Wei, Li Dongsheng, et al. Cell-free and concentrated ascites reinfusion therapy for patients with decompensated cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(2): 247-250.
[4]	Zhang Yu, Liu Fuquan. Precision technique and rational shunt in transjugular intrahepatic portosystemic shunt [J]. Journal of Practical Hepatology, 2022, 25(1): 5-8.
[5]	Chen Jing, Zhu Yueyong. Non-invasive diagnosis of portal hypertension in patients with liver cirrhosis: serum markers or imaging? [J]. Journal of Practical Hepatology, 2022, 25(1): 9-12.
[6]	Li Yanle, Liu Xiaoyu, Yao Jianning, et al. Serum ammonia level changes and its correlation to cognitive impairment in patients with hepatitis B cirrhosis and hepatic encephalopathy [J]. Journal of Practical Hepatology, 2022, 25(1): 74-78.
[7]	Yu Lei, Sun Chao, Zhang Manxu. Clinical implication of serum procalcitonin and interleukin-6 levels in patients with biliary tract stone after stone removal [J]. Journal of Practical Hepatology, 2022, 25(1): 104-107.
[8]	Wu Ling, Li Feng. Administration of non-selective beta-blockers in treatment of patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2022, 25(1): 144-147.
[9]	Shi Cuicui, Liu Yanjun, Zhang Ruinan, et al. Dyslipidemia in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 859-862.
[10]	Liu Mei, Shi Yonghong, Ying Juan, et al. Prevalence of nosocomial infection and resistance of pathogens in patients with decompensated liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 863-866.
[11]	Liu Yuling, Zhen Zengguo, Wang Huijuan, et al. Effects of probiotics on intestinal barrier function of patients with liver cirrhosis complicated by spontaneous bacterial peritonitis [J]. Journal of Practical Hepatology, 2021, 24(6): 867-870.
[12]	Xing Li, Du Qianying, Jiang Yanli, et al. Impact of segmented injection of contrast agent on hepatic vein imaging by CT angiography in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 871-874.
[13]	Huang Liou, Wu Chunrong, Xu Dan, et al. Efficacy of continuous renal replacement therapy without heparinization in patients with liver cirrhosis complicated by hepatic encephalopathy [J]. Journal of Practical Hepatology, 2021, 24(6): 875-878.
[14]	Ye Dong, Zhang Junxia, LiJie, et al. Risk factors of rebleeding in hepatitis B liver cirrhotics with esophageal varices bleeding after endoscopic variceal ligation [J]. Journal of Practical Hepatology, 2021, 24(6): 879-882.
[15]	Han Chengmei, Han Yongfeng, Wang Chunhua. Risk factors for acute kidney injury in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 883-886.